Start with 10 mg BID for anxiety
For anxiety treatment in adults, begin propranolol at 10 mg twice daily rather than 20 mg BID. This lower starting dose minimizes cardiovascular side effects while providing adequate anxiolytic coverage, with the option to titrate upward based on response and tolerability.
Rationale for Lower Starting Dose
The evidence for propranolol in anxiety is limited but informative. A 2012 study directly comparing 20 mg versus 40 mg propranolol for perioperative anxiety found that 20 mg provided significant anxiety reduction with minimal side effects, while 40 mg caused bradycardia in 25% and hypotension in 10% of patients 1. This suggests starting even lower (10 mg BID = 20 mg total daily) is prudent for chronic anxiety management where you're not targeting acute situational stress.
The FDA-approved dosing for propranolol extended-release in hypertension starts at 80 mg daily 2, but this is for cardiovascular indications. For anxiety, the therapeutic range is substantially lower—studies typically use 20-40 mg once to three times daily 3.
Clinical Approach
Starting regimen:
- Begin 10 mg twice daily (morning and early afternoon to avoid sleep disruption)
- Assess response after 3-7 days
- If inadequate response and no side effects, increase to 20 mg BID
- Maximum effective dose for anxiety typically 40 mg TID, though most patients respond to lower doses
Monitor specifically for:
- Heart rate <60 bpm (check baseline HR before starting)
- Systolic BP <90 mmHg
- Fatigue, dizziness, or sleep disturbance
- Worsening mood (propranolol may induce depression in predisposed patients) 4
Evidence Quality and Limitations
The evidence base for propranolol in generalized anxiety disorder is weak. A 2016 systematic review found insufficient evidence to support routine use in anxiety disorders 5, and a 2025 meta-analysis confirmed no benefit over placebo or benzodiazepines for social phobia or panic disorder 6. However, propranolol may be effective for:
- Performance anxiety (public speaking, social situations with somatic symptoms)
- Anxiety with prominent cardiovascular symptoms (palpitations, tremor, tachycardia) 3
- Situational anxiety of recent onset rather than chronic generalized anxiety 3
Critical Caveats
Absolute contraindications:
- Asthma or reactive airway disease
- Heart block (second or third degree)
- Decompensated heart failure
- Bradycardia <50 bpm
Relative contraindications:
- History of depression (use cautiously)
- Diabetes (may mask hypoglycemia symptoms)
- Peripheral vascular disease
The most recent high-quality evidence (2025) shows propranolol lacks robust efficacy for generalized anxiety disorders 6. Consider this a second-line option when SSRIs are contraindicated or for anxiety with prominent somatic/cardiovascular symptoms. The lower starting dose of 10 mg BID balances potential benefit against cardiovascular risks while allowing safe titration if needed.
If no response after 4 weeks at adequate doses (30-40 mg BID), discontinue and consider alternative treatments 3.